Background. Piperacillin/tazobactam (PTZ) is a carbapenem-sparing option for AmpC-repressed organisms. Current strategies of dosing PTZ focus on prolonging fT > minimum inhibitory concentration (MIC), lowering C:MIC ratios. The objective of this study was to determine the effect of physiologic PTZ concentration on the emergence of resistance among clinical isolates of Klebsiella aerogenes (KA).
Background. Current IDSA guidelines recommend targeting a vancomycin trough between 15 and 20 mg/L to achieve an AUC/MIC ≥ 400; however, recent literature shows increased rates of nephrotoxicity within this range and the target AUC/ MIC ratio may be achieved with lower troughs. We sought to determine whether a vancomycin AUC-based dosing protocol and spreadsheet-based calculator, using one-compartment population-based dosing and two steady-state serum levels, accurately predicted AUC/MIC ratio in patients with moderate to severe Staphylococcus aureus infections.
Methods. A retrospective analysis of 60 adult patients treated with vancomycin for culture-confirmed S. aureus was conducted. The primary outcome was percent of patients who met the AUC/MIC goal of ≥400. Secondary outcomes included: mean initial trough concentration in patients who met the AUC/MIC goal compared with those who did not; correlation of two different methods of AUC-estimation with the patient's actual AUC; percentage of patients meeting AUC/MIC goal stratified by initial trough concentrations, age, weight, and indication; and percentage of patients meeting the AUC goal stratified by the same variables. Results were analyzed using descriptive statistics and calculations were performed using SPSS.
Results. The median age (range) was 55 (22-86) and 52% were male. Eightythree percent of patients achieved an initial AUC/MIC ≥ 400, including 93% with serum troughs between 10 and 14.9 mg/L. Patients who met the AUC/MIC goal had an average trough of 13.5 mg/L, whereas those who did not had an average trough of 7.8 mg/L (P < 0.001). AUC estimation using population pharmacokinetics was significantly correlated with actual AUC (P = 0.011); however, this was not a strong correlation (r = 0.340). Subgroup analysis based on age, weight, and indication identified areas for improvement in the empiric dosing protocol at our institution. Background. β-Lactam exposure is frequently documented to be inadequate in critically ill patients implying that therapeutic drug monitoring (TDM) may be necessary to optimize efficacy. Practical barriers to implementation of TDM for β-lactam/β-lactamase inhibitor combinations include potential chemical instability as well as the need to assay both drug components.
Conclusion. Use of the vancomycin AUC-based dosing
Methods. First, ex-vivo stability studies of piperacillin/tazobactam (PIP/TZB) were performed at 1, 10, and 100 mg/L concentrations in human plasma. Spiked plasma samples were stored at room temperature for 4 hours and then at 4°C for 72 hours to mimic the conditions of routine handling. Second, a pilot study using discarded clinical laboratory samples was conducted to ascertain the feasibility of such a method for PIP/TZB TDM. Consecutive patients initiated on PIP/TZB within 24 hours of admission to the medical intensive care unit were screened for enrollment. Patients receiving less than 48 hours of therapy and those requiring renal replacement therapy were excluded. Laboratory samples were collected following their intended use and assayed for PIP and TZB using LC-MS/MS. Clinical patient data were obtained retrospectively.
Results. In the ex vivo studies, both PIP and TZB were stable at 100 mg/L for up to 48 hours at 4˚C; however, at lower drug concentrations there was unacceptable (>15%) loss after 24 hours. Thirty-two subjects contributed a total of 136 clinical samples for secondary analysis. Patients were a mean (SD) of 64 (15) years old with estimated creatinine clearance of 97 (61) mL/minute. The assay was linear over a range of 1-100 μg/mL and 0.5-50 μg/mL for PIP and TZB, respectively. The median (fifth, 95th percentile) PIP and TZB concentrations were 26.30 (1.78, 112.00) and 7.55 (0.95, 23.00) mg/L, respectively. A strong linear relationship (R 2 0.84) was found between TZB and PIP concentrations (figure).
Conclusion. PIP and TZB concentrations are strongly correlated permitting evaluation of PIP as the key analyte. Plasma samples for PIP/TZB should be frozen
